SOLEUS CAPITAL MANAGEMENT L P
Q4 2021 Form 13-F

GREENWICH, CONNECTICUT
CIK 0001802630 · CRD 294459 · SEC-registered investment adviser
$998.8M Reported Value Total

SOLEUS CAPITAL MANAGEMENT, L.P. reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $1,143,464,698, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
14 funds · $3.8B gross asset value
Hedge Fund: $3.0B · Private Equity Fund: $765.8M
Source: Form ADV filed 2026-04-27
Reported value
$998.8M
Quarter over quarter
-9.0%
Holdings
65
Top-10 concentration
54.5%

Key People

Form ADV owners & control persons
Guy Bezalel Levy
SOLE OWNER
Charles Arthur Davis
MEMBER
Stephen Nmn Friedman
MEMBER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2021 13F record

Q4 2021 13F filing summary

Q4 2021 Form 13F portfolio summary
Period of report December 31, 2021
Filed February 14, 2022
Form 13F-HR
Reported value $998.8M
Positions 65
Change in reported value +55.7%
New positions 21
Exited positions 27
Position turnover 52.2%
Top-10 concentration 54.5%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q2 2026 13F
Filed Aug 11, 2026
97 $2.9B
Q1 2026 13F
Filed May 14, 2026
93 $2.5B
Q4 2025 13F
Filed Feb 12, 2026
94 $2.7B
Q3 2025 13F
Filed Nov 14, 2025
87 $2.0B
Q2 2025 13F
Filed Aug 15, 2025
94 $1.5B
Q1 2025 13F
Filed May 15, 2025
74 $1.4B
Q4 2024 13F
Filed Feb 14, 2025
80 $1.6B
Q3 2024 13F
Filed Nov 14, 2024
86 $1.3B
Q2 2024 13F
Filed Aug 14, 2024
92 $1.1B
Q1 2024 13F
Filed May 15, 2024
90 $1.3B
Q4 2023 13F
Filed Feb 14, 2024
73 $901.2M
Q3 2023 13F
Filed Nov 14, 2023
90 $1.1B
Q2 2023 13F
Filed Aug 14, 2023
101 $899.5M
Q1 2023 13F
Filed May 15, 2023
76 $965.7M
Q4 2022 13F
Filed Feb 14, 2023
72 $697.1M
Q3 2022 13F
Filed Nov 14, 2022
75 $736.0M
Q2 2022 13F
Filed Aug 15, 2022
70 $641.0M
Q1 2022 13F
Filed May 16, 2022
63 $775.1M
Q4 2021 13F
Filed Feb 14, 2022
65 $998.8M
Q3 2021 13F
Filed Nov 15, 2021
70 $641.7M

7 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q4 2021

Largest Q4 2021 13F positions by reported value
# Holding Reported value % of portfolio
1 XBI P SPDR SER TR $144.7M 14.48%
2 IWM P ISHARES TR $113.1M 11.32%
3 LNTH LANTHEUS HLDGS INC $51.0M 5.1%
4 EPIX ESSA PHARMA INC $50.1M 5.01%
5 BCAB BIOATLA INC $49.4M 4.94%
6 UTHR UNITED THERAPEUTICS CORP DEL $35.5M 3.55%
7 AZN ASTRAZENECA PLC $27.9M 2.79%
8 SRDX SURMODICS INC $25.7M 2.57%
9 ENTA ENANTA PHARMACEUTICALS INC $23.8M 2.38%
10 THTXXXXX THERATECHNOLOGIES INC $23.3M 2.33%
11 NPCE NEUROPACE INC $23.3M 2.33%
12 FGEN FIBROGEN INC $21.9M 2.19%
13 NRIX NURIX THERAPEUTICS INC $21.5M 2.15%
14 NTRA NATERA INC $21.3M 2.13%
15 IRMD IRADIMED CORP $20.8M 2.08%
16 SNN SMITH & NEPHEW PLC $20.5M 2.06%
17 DICE DICE THERAPEUTICS INC $20.5M 2.05%
18 APEN APOLLO ENDOSURGERY INC $19.3M 1.94%
19 EDAP EDAP TMS S A $18.9M 1.89%
20 ORGO ORGANOGENESIS HLDGS INC $18.5M 1.85%

Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings